chronic heart failure
Conditions
Interventions
dapagliflozin group:Dagliazin was taken orally 10mg/ day
placebo group:Oral placebo was taken orally 10mg/ day
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged over 18 years old; 2. Patients should undergo echocardiography before the test. Left ventricular ejection fraction (LVEF); 40%, New York Heart Association (NYHA) class II, patients receiving standard heart failure medication; 3. Plasma NT-proBNP greater than 600 pg/mL. Plasma NT-proBNP greater than 900 pg/mL in heart failure complicated with atrial fibrillation or atrial flutter; 4. Cardiac assist devices can still be incorporated (including ICD, CRT-D, or both).
Exclusion criteria
Exclusion criteria: 1. Patients who have taken dapagliflozin before being included in the study; 2. Those who have serious adverse reactions to SGLT2 inhibitors; 3. Hypotension or blood pressure less than 105/70 mmHg; 4. Acute renal insufficiency or chronic kidney disease 5) Liver dysfunction; 6. Pregnant or lactating women; 7. Malignant tumors (under active treatment) or other life-threatening diseases; 8. Severe mental illness; 9. The doctor believes that the patient is not suitable for taking dapagliflozin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Heart Rate Variability;ventricular arrhythmias; | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma renin activity;Angiotensin I;lasma aldosterone;Angiotensin II;left ventricular end-diastolic diameter;left ventricular end-systolic diameter;ejection fraction;left ventricular mass index; | — |
Countries
China
Contacts
Public ContactTang Baopeng
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed